Generate Biomedicines, Inc. GENB

$13.69 -0.80% Close, Oct 2, 2026 · NASDAQ · Market cap $1.75B

Next earnings report: Nov 5, 2026

Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.

Three things to know

The stock is 33% below its highest close of the past year.

PromtFinance scores

Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.

Growth—Not enough data

How fast revenue, earnings and cash flow are growing.

Quality—Not enough data

Returns on capital, margins, earnings quality and balance-sheet strength.

Return on invested capitalBottom 45%

Value—Not enough data

How cheap the shares are relative to earnings, cash flow and their own history.

Momentum—Not enough data

Strength and persistence of the price trend, including versus the S&P 500.

6-month returnBottom 43%

Revisions23Very weak

Earnings surprises and analyst sentiment (estimate-revision history is being collected).

Average EPS surprise, last 4 quartersBottom 38%
Consecutive EPS beatsBottom 20%
Upside to consensus price targetTop 39%

Stability60Neutral

Low volatility, shallow drawdowns, low market sensitivity and modest leverage.

Volatility, 60 days (lower is better)Bottom 17%
Maximum drawdown, 3 yearsTop 6%

Fundamental momentum

Measure	Now (TTM)	Year / quarter before		Sector rank
Return on invested capital	-26.2%	—		Bottom 45%

Earnings and expectations

Earnings momentum

Consecutive EPS beats: 0
Beats in the last 8 reports: 0 of 1
Average EPS surprise, last 4: -2.3%
Average 2-day reaction, last 8: -4.1%
Positive 20 days after report: 1 of 1

Analysts

Consensus price target: $26.00
Target vs current price: +89.9%

How the stock reacted to recent reports

Report date	EPS surprise	2 days	5 days	20 days	60 days
Aug 6, 2026	-2.3%	-4.1%	+4.1%	+12.4%	—

Returns from the close before each report. Past reactions do not determine future ones.

Earnings history

Report date	EPS	Estimate	Surprise	Revenue
Aug 6, 2026	-$0.52	-$0.51	-2.3%	$6.3M

Technical state

Trend checklist

✗ Price above 20-day average
✗ Price above 50-day average
✗ MACD histogram positive

Trend quality

Days above the 50-day average: 0
50-day average slope (20 days): +1.5%
Distance from 50-day average: -11.5%
RSI (14): 36.3
Relative volume: 1.06×

Risk and drawdowns

Volatility, 60 days (annualized): 80.9%
Current drawdown from 1-year high: -32.8%
Maximum drawdown, 3 years: -32.8%

Largest declines in the past six years

From peak	To low	Decline	Length	Recovery
Aug 25, 2026	Oct 2, 2026	-32.8%	27 days	Not yet recovered
May 13, 2026	Jun 2, 2026	-26.2%	13 days	15 days (Jun 24, 2026)
Jul 2, 2026	Jul 29, 2026	-24.9%	18 days	18 days (Aug 24, 2026)
Apr 2, 2026	Apr 10, 2026	-17.0%	5 days	16 days (May 4, 2026)
Mar 12, 2026	Mar 27, 2026	-13.9%	11 days	3 days (Apr 1, 2026)

Declines of 10% or more from a closing high, measured on daily closes.

Financial statements

Market cap: $1.75B

	FY 2024	FY 2025
Revenue	$20.5M	$31.9M
Gross profit	$20.5M	$31.9M
Operating income	-$196.9M	-$235.1M
Net income	-$173.8M	-$203.2M
EPS (diluted)	-$1.68	-$4.98

	Q1 2026	Q2 2026
Revenue	$7.2M	$6.3M
Net income	-$61.4M	-$67.3M
EPS (diluted)	-$0.54	-$0.52

	FY 2024	FY 2025
Operating cash flow	-$117.8M	-$200.6M
Capital expenditure	-$3.4M	-$3.5M
Free cash flow	-$121.2M	-$204.1M
Dividends paid	$0	$0
Net share buybacks	$0	$0

Cash outflows are shown as negative numbers.

Cash and short-term investments: $457.4M
Total assets: $561.7M
Total liabilities: $105.6M
Total debt: $62.6M
Net debt: -$72.7M
Shareholders’ equity: $456.0M

As of Jun 30, 2026 (filed Aug 6, 2026).

Short interest

Shares sold short: 7,180,013
Days to cover: 7.24
Change vs previous report: -3.7%

FINRA short interest, settlement date Sep 15, 2026.